Mylan Introduces New Triple Combo Once-Daily HIV Treatment

Mylan recently announced the introduction of its FDA-approved triple combination once-daily HIV treatment, efavirenz, lamivudine, and tenofovir disoproxol fumarate (Symfi), in the United States, according to a company press release.

Symfi is approved in 600 mg/300 mg/300 mg tablets as a once-daily, single-tablet regimen, indicated as a complete regimen for the treatment of HIV-1 infection in adult and children weighing at least 40 kg.

The introduction follows the FDA’s recent approval of 2 Mylan ARVs: Cimduo (lamivudine and tenofovir disoproxil fumarate) 300 mg/300 mg tablets and Symfi Lo (efavirenz, lamivudine, and tenofovir disoproxil fumarate) 400 mg/300 mg/300 mg tablets. Symfi Lo is indicated to treat adult and pediatric patients with HIV-1 weighing at least 35 kg and Cimduo is a once-daily combination of nucleo(t)side reverse transcriptase inhibitors and is indicated in combination with other antiretroviral drugs to treat the same population.

Symfi and Symfi Lo feature the same triple combination of molecules. However, Symfi Lo features a reduced dose whereas Symfi uses a dosing similar to other efavirenz products already on the market.

Mylan hopes to reduce the high cost of HIV treatment in the United States by offering these ARVs at a price significantly discounted from the price of competing products, according to the press release.

Mylan launched Symfi-Lo in March 2018 and anticipates it will launch Cimduo and Symfi in the second quarter of 2018.

Reference

Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment in the U.S. [news release]. Mylan’s website. http://newsroom.mylan.com/2018-03-28-Mylan-Introduces-Symfi-TM-Triple-Combo-Once-Daily-HIV-Treatment-in-the-U-S. Accessed March 29, 2018.